From: Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy
Variables | Patients (n = 523) | ||
---|---|---|---|
Number | Percentage (%) | Mean (SD) | |
Age at diagnosis (years) | Â | Â | 58.1 (7.1) |
Race | Â | Â | Â |
 African-American | 44 | 8.4 |  |
 European-American | 479 | 91.6 |  |
Body mass index at diagnosis (kg/m2) | Â | Â | 26.9 (3.7) |
Pathological stagea | Â | Â | Â |
 Local | 360 | 68.8 |  |
 Regional | 163 | 31.2 |  |
Gleason score | Â | Â | Â |
 ≤6 | 252 | 48.2 |  |
 7(3 + 4) | 188 | 35.9 |  |
 7(4 + 3) | 45 | 8.6 |  |
 8–10 | 38 | 7.3 |  |
PSA at diagnosis (ng/mL)b | Â | Â | Â |
 0−3.9 | 80 | 16.2 |  |
 4−9.9 | 313 | 63.5 |  |
 10−19.9 | 67 | 13.6 |  |
 ≥20 | 33 | 6.7 |  |
Recurrenceb | Â | Â | Â |
 No recurrence | 323 | 74.9 |  |
 Recurrence | 108 | 25.1 |  |
Follow-up time (years)b | Â | Â | 8.0 (4.2) |